Abstract
Magnetic mesoporous nanocomposites are emerging as a significant new material to improve the effectiveness of cancer treatment and enhance the availability of drug therapy. Thus, the core–shell structure magnetic mesoporous nanocomposites (Fe3O4@SiO2@LDH) were synthesized with an average diameter of about 100 nm and used as methotrexate (MTX) carriers for cancer therapy. As an important biological material, Fe3O4@SiO2@LDH exhibited higher superparamagnetic behavior and biocompatibility, and the drugs can be loaded in the channels of the mesoporous silica and the interlayer of layered double hydroxides (LDH). The embedding rate of magnetic mesoporous silica (Fe3O4@SiO2) and LDH were 60.32 % and 0.67 %, respectively, and the release rate of the drug delivery systems (Fe3O4@SiO2@LDH-MTX) was 66.81 %. In addition, LDH as a kind of pH-sensitive material was adopted for controlled drug release and WST-1 assays in cancer cells (Hela) demonstrated that Fe3O4@SiO2@LDH-MTX presented high anti-tumor activity, while the carriers were nearly non-toxic. Therefore, all the results suggested that the magnetic nanocomposites can be employed to deliver MTX, and would be applied in the field of cancer therapy in the future.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
